Lumos Pharma Inc. | NLNK - Selling And Administration Expenses

Newlink Genetics reported $4.48M in Selling and Administration Expenses for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Selling And Administration Expenses Change
Agenus AGEN:US USD 25.04M 6.93M
Bristol Myers Squibb BMY:US USD 2.27B 336M
Capricor Therapeutics CAPR:US USD 2.79M 229.48K
Celldex Therapeutics CLDX:US USD 6.6M 68K
Eli Lilly And LLY:US USD 1.64B 29M
Idera Pharmaceuticals IDRA:US USD 2.27M 391K
Intrexon XON:US USD 11.51M 1.37M
Merk MRK:US USD 2.63B 134M
Nektar Therapeutics NKTR:US USD 21.94M 595K
Newlink Genetics NLNK:US USD 4.48M 567K
Pfizer PFE:US USD 4.87B 1.33B
Prothena PRTA:US USD 13.12M 1.14M
Sarepta Therapeutics SRPT:US USD 120.48M 15.69M
Vascular Biogenics VBLT:US USD 1.92M 1.82M
YTE INCY:US USD 272.82M 6.36M